Skip to main content
. 2019 Dec 16;10:386. doi: 10.1186/s13287-019-1518-0

Table 2.

Research regarding application of gene modified MSCs in preclinical ARDS models

Candidate gene Engineering vector Animal species ARDS model MSC source MSC species MSC dose Administration route References
CXCR4 Lentiviral vector Rat LPS-induced Bone marrow Rat 1 × 106 Tail vein [53]
EP2 Lentiviral vector Mice LPS-induced Bone marrow Mice 5 × 105 Tail vein [54]
sST2 Lentiviral vector Mice LPS-induced Adipose tissue Human 1 × 106 Tail vein [60]
ACE2 Lentiviral vector Mice LPS-induced Bone marrow Mice 5 × 105 Tail vein [63]
KGF Lentiviral vector Mice LPS-induced Bone marrow Mice 5 × 105 Tail vein [67]
HGF Adenoviral vector Mice radiation-induced Bone marrow Human 1 × 106 Tail vein [72]
Ang-1 Lentiviral vector Mice LPS-induced Bone marrow Mice 1 × 105 Jugular vein [79]
Ang-1 Nuclear-targeting electroporation Mice LPS-induced Bone marrow Mice 2.5 × 105 Jugular vein [80]
MnSOD Lentiviral vector Mice radiation-induced Bone marrow Human 1 × 106 Tail vein [85]
HO-1 Lentiviral vector Rat LPS-induced Bone marrow Rat 5 × 105 Tail vein [86]

ARDS acute respiratory distress syndrome, CXCR4 chemokine receptor 4, LPS lipopolysaccharide, EP2 E-prostanoid 2, sST2 soluble IL-1 receptor-like-1, ACE2 angiotensin-converting enzyme 2, KGF keratinocyte growth factor; HGF, hepatocyte growth factor, Ang-1 angiopoietin-1, HO-1 heme oxygenase-1, MnSOD manganese superoxide dismutase